Clinical and Translational Allergy最新文献

{"title":"Association of Mitochondrial DNA Copy Number With Atopic Dermatitis in Children","authors":"Ju Chang-Chien,&nbsp;Tzu-Han Su,&nbsp;Xin-Hui Lin,&nbsp;Yu-Hsuan Liao,&nbsp;Yi-Fen Tsai,&nbsp;Yin Szu,&nbsp;Yen-Chieh Meng,&nbsp;Ming-Ling Kuo,&nbsp;Hui-Ju Tsai,&nbsp;Tsung-Chieh Yao","doi":"10.1002/clt2.70214","DOIUrl":"10.1002/clt2.70214","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Mitochondrial DNA copy number (mtDNA-CN), a marker associated with mitochondrial function and cellular health, has been implicated in several chronic inflammatory diseases. Atopic dermatitis is a common chronic inflammatory skin disorder, yet the relationship between mtDNA-CN and childhood atopic dermatitis remains unclear. This study aimed to investigate the association between mtDNA-CN and atopic dermatitis in a population-based cohort of school-aged children.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We included 1329 singleton children (56.4% boys; mean age ± standard deviation: 6.5 ± 0.5 years) from the Longitudinal Investigation of Global Health in Taiwanese Schoolchildren (LIGHTS) cohort. Genomic DNA was extracted from peripheral blood, and mtDNA-CN was quantified by real-time quantitative polymerase chain reaction. Multivariable logistic regression models were applied.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Among the 1329 children, 328 (24.7%) children had physician-diagnosed atopic dermatitis. Mean mtDNA-CN was lower in children with atopic dermatitis than in those without (289.62 ± 102.06 vs. 299.47 ± 91.90; <i>p</i> = 0.03). Each one-unit increase in log-transformed mtDNA-CN was associated with 28% lower odds of atopic dermatitis after adjustment for potential confounders (adjusted odds ratio: 0.72; 95% confidence interval: 0.54–0.96). Subgroup analyses showed that this inverse association was more pronounced among children breastfed for ≥ 3 months and those with a birth weight ≥ 2500 g.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>This study provides novel evidence of an inverse association between mtDNA-CN and atopic dermatitis in children. Further longitudinal and mechanistic studies are warranted to confirm these findings and to evaluate the potential utility of mtDNA-CN as a biomarker for atopic dermatitis.</p>\u0000 </section>\u0000 </div>","PeriodicalId":10334,"journal":{"name":"Clinical and Translational Allergy","volume":"16 10","pages":""},"PeriodicalIF":4.2,"publicationDate":"2026-10-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13657800/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149164439","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Experiences From the First Year of Using Garadacimab to Treat Hereditary Angioedema and Acquired Angioedema","authors":"Markus Magerl,&nbsp;Kathrin Schön,&nbsp;Janine Ruhe,&nbsp;Felix Aulenbacher,&nbsp;Leonie Shirin Herzog,&nbsp;Thomas Buttgereit","doi":"10.1002/clt2.70205","DOIUrl":"10.1002/clt2.70205","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Garadacimab, a first-in-class, recombinant monoclonal antibody targeting activated FXII, is available in Germany for long-term prophylaxis (LTP) of hereditary angioedema (HAE) since March 2025. We aimed to examine garadacimab real-life treatment outcomes at our Berlin Angioedema Center of Reference and Excellence (ACARE), the reasons for switching therapies, and approaches to tailoring treatment individually.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>In total, 29 patients (27 patients with HAE and 2 patients with angioedema due to acquired C1 inhibitor deficiency) were treated in regular care with garadacimab; 3 patients discontinued garadacimab due to lack of efficacy after loading dose or second dose and were excluded from analysis due to insufficient follow up. Ultimately, 26 patients were monitored for 26 weeks (median) using the angioedema control test (AECT) and the angioedema quality of life questionnaire (AE-QoL). In seven patients, garadacimab from the open-label-VANGUARD study was continued in regular care. Patients who had previously participated in the study—provided they were symptom-free—were offered the option, upon transitioning to routine care, to extend the interval between injections by alternating between three and four days. Patients who were switched to garadacimab in routine care were offered the same option if they were completely symptom-free 2 months after starting the therapy.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Overall, 16 patients switched from previous LTP to garadacimab mostly at the end of their individual treatment interval and due to the prospect of higher efficacy and convenience. The injection interval could be extended in most patients (median, 42 days, range 31–56). The mean AECT and AE-QoL improved clinically meaningfully, regardless of previous treatment (9.2–14.4 and 35.5–14.9 points, respectively), however, improvement in patients switched from previous LTP was less pronounced when compared to patients that switched from on-demand treatment (11.2–14.5 vs. 6.7–14.2 points and 29.4–14.3 vs. 43.1–15.7 points, respectively). No side effects were reported.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Garadacimab showed high efficacy and safety and the gradual extension of injection intervals presented underline its potential for longer dosing intervals that may further reduce treatment burden.</p>\u0000 </section>\u0000 </div>","PeriodicalId":10334,"journal":{"name":"Clinical and Translational Allergy","volume":"16 10","pages":""},"PeriodicalIF":4.2,"publicationDate":"2026-10-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13654816/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149166323","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-World Effectiveness and Safety of Triple-Mite SCIT With Dermatophagoides and Blomia tropicalis","authors":"José Carlos García-Robaina,&nbsp;Cristina González-Colino,&nbsp;Guacimara Lucia Hernández-Santana,&nbsp;Elena Rodríguez-Plata,&nbsp;Mónica González-Afonso,&nbsp;Ariel Callero,&nbsp;Juan Antonio Martínez-Tadeo,&nbsp;María José Menés,&nbsp;Miguel Casanovas,&nbsp;Yara Ruiz García,&nbsp;Judith Díaz-García","doi":"10.1002/clt2.70217","DOIUrl":"https://doi.org/10.1002/clt2.70217","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>House dust mite (HDM)-induced respiratory allergy is a major global health problem. Species distribution varies by region and climate; <i>Blomia tropicalis</i> is prevalent in tropical and subtropical areas and often coexists with <i>Dermatophagoides</i> spp. Although allergen immunotherapy (AIT) reduces symptoms and medication use, real-world evidence for formulations including <i>B. tropicalis</i> remains limited.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objectives</h3>\u0000 \u0000 <p>To evaluate the real-world effectiveness and safety of triple-mite subcutaneous immunotherapy (SCIT) with glutaraldehyde-polymerized extracts of <i>Dermatophagoides pteronyssinus</i>, <i>Dermatophagoides farinae</i>, and <i>B. tropicalis</i>.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Clinical records of 208 patients (5–65 years) with mite-induced allergic rhinoconjunctivitis, with or without asthma, sensitized to these mites were analyzed. All received ≥ 12 months of SCIT. Follow-up extended up to 5 years. Effectiveness was assessed annually using mixed models for repeated measures based on combined symptom and medication scores for rhinoconjunctivitis (RCSMS) and asthma (ACSMS), and individual symptom and medication scores. Safety was evaluated by recording adverse reactions.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Significant and sustained improvements were observed. Adjusted LS-mean RCSMS decreased from 3.97 at baseline to 2.26 at 1 year and 1.24 at 5 years (−43.1% and −68.8%; <i>p</i> &lt; 0.001). ACSMS decreased from 2.74 to 1.36 and 0.46 (−50.5% and −83.3%). Symptom improvement was early and accompanied by progressive reductions in medication use. Safety was favourable, with one mild grade 1 systemic reaction (0.48% of patients; 0.015% per injection), resolving without treatment modification.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Triple-mite SCIT was associated with sustained, clinically meaningful reductions in symptoms and medication use, and showed a favourable safety profile, supporting a favourable benefit–risk balance in regions where these mites coexist.</p>\u0000 </section>\u0000 </div>","PeriodicalId":10334,"journal":{"name":"Clinical and Translational Allergy","volume":"16 10","pages":""},"PeriodicalIF":4.2,"publicationDate":"2026-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/clt2.70217","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149146482","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Achieving Remission in Chronic Rhinosinusitis With Nasal Polyps Depends on Practical Utilization of Current Criteria and Does not Reflect Therapy Response: Results From a Multi-National Cohort","authors":"Jan Hagemann,&nbsp;Tobias Albrecht,&nbsp;Sanna Toppila-Salmi,&nbsp;Marie Lundberg,&nbsp;Annina Lyly,&nbsp;Katharina Geißler,&nbsp;Friederike Bärhold,&nbsp;Caroline Beutner,&nbsp;Inga Nierkamp,&nbsp;Mandy Cuevas,&nbsp;Nadine Gunder,&nbsp;Adam Chaker,&nbsp;Moritz Gröger,&nbsp;Ludger Klimek,&nbsp;Sven Becker","doi":"10.1002/clt2.70211","DOIUrl":"10.1002/clt2.70211","url":null,"abstract":"&lt;p&gt;Recent advances in biologic therapy for severe chronic rhinosinusitis with nasal polyps (CRSwNP), asthma, and other type-2 inflammatory diseases have raised attention to patient-reported outcomes. Long and sustained effects of biologic drugs targeting IgE, TSLP, IL-4R, and IL-5 signaling for CRS and/or asthma have created a situation where &lt;i&gt;Remission&lt;/i&gt; and other controlled states are observable long-term. However, well-defined and meaningful diagnostic biomarkers predicting therapeutic &lt;i&gt;Response&lt;/i&gt; are yet to be found. Furthermore, &lt;i&gt;Remission&lt;/i&gt; and &lt;i&gt;Control&lt;/i&gt; states require unambiguous definitions to enable structured communication between physicians and patients [&lt;span&gt;1&lt;/span&gt;]. In a pivotal effort, an expert consensus of renowned specialists in ENT, pulmonology, allergology, and immunology has suggested criteria of how to define disease states such as &lt;i&gt;Control&lt;/i&gt; and &lt;i&gt;Remission&lt;/i&gt; and therapeutic goals in CRSwNP, omitting physician-reported parameters for the definition of &lt;i&gt;Control&lt;/i&gt; and emphasizing persistent absence of burdensome symptoms for patients [&lt;span&gt;2&lt;/span&gt;].&lt;/p&gt;&lt;p&gt;In an orchestrated and multi-national effort applying these recently suggested and novel criteria to a large cohort of biologic drug applications (&lt;i&gt;n&lt;/i&gt; = 369), we identified three main findings: (1) Disease &lt;i&gt;Remission&lt;/i&gt;, defined as sustained &lt;i&gt;Control&lt;/i&gt; for &gt; 12 months in absence of rescue treatments and active disease, was achieved only in a minority of cases, despite partial or full &lt;i&gt;Response&lt;/i&gt; to biologic therapy; (2) under biologic drugs, disease &lt;i&gt;Control&lt;/i&gt; and &lt;i&gt;Remission&lt;/i&gt; are therapeutic goals possibly facilitated in the presence of co-morbidities such as comorbid asthma and salicylate intolerance (N-ERD), and (3) the practical application of current definitions for disease &lt;i&gt;Control&lt;/i&gt; and &lt;i&gt;Remission&lt;/i&gt; is unfolding substantial challenges with regards to cut-offs, inter-observer variability, and choice of reporting method. Furthermore, we feel that these definitions could be further improved by an orchestrated and data-driven approach to compensate for these challenges. In addition, incorporating the status of known co-morbidities and possible side-effects of the therapy in use might be important with regards to &lt;i&gt;Remission&lt;/i&gt; as a therapeutic goal.&lt;/p&gt;&lt;p&gt;Rhinologic centers in Germany and Finland assessed &lt;i&gt;Control&lt;/i&gt; and &lt;i&gt;Remission&lt;/i&gt; in &lt;i&gt;n&lt;/i&gt; = 369 patients with severe CRSwNP (mean age 55.2 years), treated with Dupilumab (&lt;i&gt;n&lt;/i&gt; = 274), Mepolizumab (&lt;i&gt;n&lt;/i&gt; = 72), or Omalizumab (&lt;i&gt;n&lt;/i&gt; = 29) for up to 36 months (total &lt;i&gt;n&lt;/i&gt; = 88 after 3 years observation, Supporting Information S1: Figure 1). Six patients switched biologic drugs (all to Dupilumab) during the observation period but have been observed more than 12 months for each individual course of biologic. The study respected the Declaration of Helsinki and Ethics approval was given to each center separately under local regulations fo","PeriodicalId":10334,"journal":{"name":"Clinical and Translational Allergy","volume":"16 10","pages":""},"PeriodicalIF":4.2,"publicationDate":"2026-10-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13635686/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149104931","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Short-Course Subcutaneous Immunotherapy With Mannan-Conjugated Birch Pollen Allergoids: Consistent Clinical and Immunological Improvements","authors":"Esther Raskopf,&nbsp;Sofia Passamera,&nbsp;Ludger Klimek,&nbsp;Oliver Pfaar,&nbsp;Christian Neuhof,&nbsp;Anna Rybachuk,&nbsp;Nadine Katzke,&nbsp;Hacer Sahin,&nbsp;Silke Allekotte,&nbsp;Ralph Mösges,&nbsp;Laura Day,&nbsp;José Luis Subiza,&nbsp;Miguel Casanovas,&nbsp;Mandy Cuevas,&nbsp;Sandra del Pozo","doi":"10.1002/clt2.70209","DOIUrl":"10.1002/clt2.70209","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>The mannan-conjugated birch pollen polymerised allergoid EP-088_T502 has previously been shown to reduce allergic symptoms and anti-allergic medication use during the birch pollen season. This confirmatory phase III trial aimed to evaluate the efficacy, safety, tolerability, and immunologic effects of EP-088_T502 administered as eight subcutaneous injections over six pre-seasonal treatment visits.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>In this double-blind, placebo-controlled (DBPC) trial, 278 participants with birch pollen–induced allergic rhinoconjunctivitis (ARC) received either placebo or a cumulative dose of 28,000 mannan therapeutic units (mTU) of EP-088_T502. The primary efficacy endpoint was the combined symptom and medication score (CSMS) during the peak birch pollen season. Safety, tolerability, health-related quality of life (QoL), and immunologic parameters were also assessed.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>In the full analysis set (FAS), EP-088_T502 significantly reduced the CSMS during the peak birch pollen season compared with placebo (mean absolute difference [MAD] −0.31; 95% confidence interval [CI], −0.56 to −0.05; <i>p</i> = 0.0169). In the per-protocol (PP) and complete-case sets, the corresponding MADs were −0.36 (<i>p</i> = 0.012) and −0.51 (<i>p</i> = 0.013), respectively. Health-related QoL improved by 20% in the EP-088_T502 group compared with placebo during the peak season (<i>p</i> &lt; 0.005). EP-088_T502 increased Bet v 1-specific immunoglobulin G4 (IgG4) levels after treatment compared with placebo (6.4-fold; <i>p</i> &lt; 0.0001). The Bet v 1-specific immunoglobulin E (IgE)/IgG4 ratio was reduced by 73% from baseline and by 69% compared with placebo (both <i>p</i> &lt; 0.0001). Thirteen systemic allergic reactions occurred, including one grade III systemic reaction considered related to EP-088_T502.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>EP-088_T502 significantly improved symptom and medication scores in participants with birch pollen–induced ARC and induced a substantial Bet v 1-specific IgG4 response. The 28,000 mTU regimen induced a substantial immunological response and showed an acceptable safety and tolerability profile.</p>\u0000 </section>\u0000 </div>","PeriodicalId":10334,"journal":{"name":"Clinical and Translational Allergy","volume":"16 10","pages":""},"PeriodicalIF":4.2,"publicationDate":"2026-10-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13635281/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149104942","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy of Biologics in Aspirin Exacerbated Respiratory Disease","authors":"Jennifer K. Priessnitz,&nbsp;Anastasia Hagopian,&nbsp;Alison J. Patev,&nbsp;Joseph K. Han,&nbsp;Kent K. Lam","doi":"10.1002/clt2.70212","DOIUrl":"10.1002/clt2.70212","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Aspirin-exacerbated respiratory disease (AERD), also termed nonsteroidal anti-inflammatory drug exacerbated respiratory disease (NERD), is characterized by asthma, chronic rhinosinusitis with nasal polyposis, and hypersensitivity to cyclooxygenase-1 inhibitors, frequently resulting in severe, treatment-refractory airway disease. Biologic therapies targeting type 2 inflammation are increasingly used in AERD; though their relative efficacy remains incompletely defined.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We conducted a semi-systematic narrative review of biologic therapies in AERD, guided by established narrative review frameworks. PubMed/Medline, ScienceDirect, and ClinicalTrials.gov were searched for studies reporting clinical outcomes in AERD/NERD or clearly defined AERD/NERD subgroups. This review synthesizes current evidence and presents an evidence-informed clinical framework to support biologic selection in patients with AERD.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Eighteen studies identified, including randomized controlled trials, observational studies, and real-world studies. Across these studies, dupilumab was most consistently associated with improvements in both upper and lower airway outcomes. Anti–IL-5 and anti–IL-5Rα therapies reduced eosinophilia and asthma exacerbations, with variable sinonasal benefit. Omalizumab demonstrated efficacy in selected atopic phenotypes and in conjunction with aspirin therapy following desensitization. Emerging subgroup data suggests that Tezepelumab may reduce asthma exacerbations in AERD.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Current evidence suggests biologic therapies provide meaningful benefit in AERD, although available evidence is limited by small sample sizes and heterogeneous designs. Prospective comparative studies are needed to inform optimal biologic selection and sequencing.</p>\u0000 </section>\u0000 </div>","PeriodicalId":10334,"journal":{"name":"Clinical and Translational Allergy","volume":"16 10","pages":""},"PeriodicalIF":4.2,"publicationDate":"2026-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13633742/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149104978","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bioassays in Allergy: Technical Characteristics, Limitations, and Pathways to Clinical Implementation—An EAACI Position Paper","authors":"Cagatay Karaaslan,&nbsp;Oscar Palomares,&nbsp;Busra Kilic,&nbsp;Cristobalina Mayorga,&nbsp;Hans Jürgen Hoffmann,&nbsp;Bernadette Eberlein,&nbsp;Edward Knol,&nbsp;Ruben Fernandez-Santamaria,&nbsp;Joana Vitte,&nbsp;Elena Izquierdo,&nbsp;Cristina Gomez-Casado,&nbsp;Marina Perez-Gordo,&nbsp;Araceli Diaz Perales,&nbsp;Maria M. Escribese","doi":"10.1002/clt2.70210","DOIUrl":"10.1002/clt2.70210","url":null,"abstract":"<p>Bioassays offer functional readouts of immune responses through specific biomarkers, providing mechanistic insight beyond conventional serology. By capturing cellular activation, tissue-level changes, and molecular signaling, they hold promise for refining allergy diagnosis, risk stratification, and treatment monitoring, contributing to precision medicine. This review summarizes the current landscape of three allergy-relevant bioassays: basophil activation test, histology, and molecular biology-based assays. We discuss their underlying principles, clinical utilities as well as methodological and translational challenges and translational barriers. Attention is given to unmet needs such as assay standardization, reproducibility, and integration into clinical workflows. Finally, we outline future directions for research and clinical implementation, emphasizing the potential of bioassays to refine personalized management of allergic disorders. This position paper clearly distinguishes between descriptive summaries of the available evidence and the potential applicability recommendations of the EAACI Task Force, thereby enhancing clarity and interpretability for clinicians and researchers.</p>","PeriodicalId":10334,"journal":{"name":"Clinical and Translational Allergy","volume":"16 10","pages":""},"PeriodicalIF":4.2,"publicationDate":"2026-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13626604/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149104963","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-Term Ocular Outcomes of Dupilumab in Atopic Dermatitis: Results From the BioDay Registry","authors":"Nienke Veldhuis,&nbsp;Roselie E. Achten,&nbsp;Chantal M. van Luijk,&nbsp;Marlot M. van der Wal,&nbsp;Constance F. den Hartog Jager,&nbsp;Nicolaas P. A. Zuithoff,&nbsp;Mohsin El Amrani,&nbsp;Edward F. Knol,&nbsp;Femke van Wijk,&nbsp;Marlies de Graaf,&nbsp;Inge M. Haeck,&nbsp;Mor M. Dickman,&nbsp;Marjolein S. de Bruin-Weller","doi":"10.1002/clt2.70208","DOIUrl":"https://doi.org/10.1002/clt2.70208","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Dupilumab-associated ocular surface disease (DAOSD) is the most reported side effect in dupilumab-treated atopic dermatitis (AD) patients. We investigated the effect of long-term dupilumab treatment on ocular surface disease (OSD), conjunctival goblet cells (GCs), and tear fluid dupilumab levels and proteins.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>This prospective study included moderate-to-severe AD patients at the University Medical Center Utrecht, the Netherlands. Patients initiating dupilumab between February 2020–October 2022 were eligible to participate in scheduled ophthalmological examinations alongside routine dermatological examinations at baseline, week 28, and last follow-up (≥ 2 years). OSD severity was assessed using the Utrecht Ophthalmic Inflammatory and Allergic disease (UTOPIA) score, with DAOSD defined as a ≥ 3-point increase from baseline. Conjunctival GC quantity and function were assessed with impression cytology. Dupilumab levels and proteins were measured in tear fluid.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Forty-four patients were included. OSD was present in 90.9% (<i>n</i> = 40/44) of patients at all visits. DAOSD occurred in 22.7% (<i>n</i> = 10/44) of patients; 40.0% (<i>n</i> = 4/10) persisted or newly developed at last follow-up. Tear break-up time decreased while tear production increased. Tear fluid dupilumab levels and AD-related inflammatory proteins decreased over time. Conjunctival GCs decreased at last follow-up compared to baseline. Mucin5AC (MUC5AC) production in CK19-CD45-MUC5AC + cells decreased at week 28 and remained stable at last follow-up.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>OSD remained common during long-term dupilumab treatment in AD patients. Some patients developed worsening of OSD compatible with DAOSD, including delayed onset, highlighting the need for continued awareness of ocular side effects among clinicians. Reduced MUC5AC production and declining AD-related inflammatory proteins in tear fluid suggest changes in conjunctival homeostasis and ocular inflammation.</p>\u0000 </section>\u0000 </div>","PeriodicalId":10334,"journal":{"name":"Clinical and Translational Allergy","volume":"16 10","pages":""},"PeriodicalIF":4.2,"publicationDate":"2026-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/clt2.70208","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149068316","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sesame Immunotherapy: A Systematic Review and Narrative Synthesis","authors":"Joanna Zielińska,&nbsp;Katarzyna Kunkiel,&nbsp;Anna Krupa-Łaska,&nbsp;Marek Kulus,&nbsp;Katarzyna Grzela","doi":"10.1002/clt2.70206","DOIUrl":"https://doi.org/10.1002/clt2.70206","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <p>Sesame allergy is associated with severe allergic reactions, low rates of spontaneous resolution, and significant psychosocial burden. Current management relies on strict avoidance and emergency treatment. Allergen-specific immunotherapy, particularly oral immunotherapy (OIT), has emerged as a potential disease-modifying approach, but evidence for sesame allergy remains limited. A systematic search was conducted through August 2025. Eligible studies included participants of any age with confirmed sesame allergy treated with allergen immunotherapy. Primary outcomes were desensitization and sustained unresponsiveness assessed by oral food challenge. Secondary outcomes included adverse events, epinephrine use, quality of life, and mortality. Risk of bias was evaluated using Joanna Briggs Institute tools. Nine studies met the inclusion criteria, including one study identified through citation searching. The evidence consisted, primarily small cohort studies and case series. Single-allergen sesame OIT achieved high desensitization rates (approximately 85%–97%) across heterogeneous protocols and age groups. Sustained unresponsiveness was reported in a limited number of mainly pediatric cohorts. Most adverse events were mild to moderate; severe reactions requiring epinephrine were uncommon, and no deaths were reported. Adjunctive omalizumab improved tolerability in high-risk adults. Sesame OIT shows promising efficacy with an acceptable safety profile in specialized settings. However, evidence is limited by small sample sizes, heterogeneity, and short follow-up. Randomized controlled trials are needed to define optimal protocols and long-term outcomes.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Trail Registration</h3>\u0000 \u0000 <p>The protocol for this systematic review was prospectively registered in PROSPERO (International Prospective Register of Systematic Reviews; Registration number: CRD420251087250)</p>\u0000 </section>\u0000 </div>","PeriodicalId":10334,"journal":{"name":"Clinical and Translational Allergy","volume":"16 10","pages":""},"PeriodicalIF":4.2,"publicationDate":"2026-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/clt2.70206","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149068315","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Longitudinal Proteomic Signatures of Dupilumab and Tralokinumab Treated Atopic Dermatitis Patients","authors":"Wojciech Francuzik,&nbsp;Kristijan Pažur,&nbsp;Margitta Worm","doi":"10.1002/clt2.70203","DOIUrl":"10.1002/clt2.70203","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Atopic dermatitis (AD) is a chronic inflammatory disease driven by Type 2 (Th2) inflammation. Dupilumab (anti-IL-4Rα) and tralokinumab (anti-IL-13) are effective biologic therapies, but a direct comparison of their longitudinal effects on the systemic proteome is lacking. This exploratory study aimed to identify and to differentially analyze the proteomic signatures in AD patients treated with dupilumab versus tralokinumab.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>In this prospective, observational study, serum samples were collected from patients with moderate-to-severe AD at baseline and after 12 months of treatment with either dupilumab (<i>n</i> = 10) or tralokinumab (<i>n</i> = 10). A cohort of healthy controls (<i>n</i> = 12) was included for baseline comparison. Proteomic profiling was performed using a targeted 440-protein array, and data were analyzed for differential expression and pathway enrichment.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>At baseline, AD patients exhibited a distinct proteomic signature compared to healthy controls, characterized by a strong Th2 inflammatory profile and enrichment of the IL-4/IL-13 signaling pathway. After 12 months, both therapies reduced the core Th2 inflammatory signature with downregulation of key markers like CCL17. Dupilumab induced a broader immunomodulation, showing a more pronounced upregulation of Th1 associated proteins compared to tralokinumab. Furthermore, the therapies had opposing effects on tissue repair and metabolic proteins; dupilumab treatment led to a decrease in TNFSF11 and Sclerostin (SOST), while these were increased after tralokinumab treatment.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Dupilumab and tralokinumab effectively target the Th2 axis in AD but their longitudinal systemic immune modulation differs in respect to Th1-Th17 and tissue repair markers.</p>\u0000 </section>\u0000 </div>","PeriodicalId":10334,"journal":{"name":"Clinical and Translational Allergy","volume":"16 9","pages":""},"PeriodicalIF":4.2,"publicationDate":"2026-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149036827","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}